Business Wire

Regula Launches Identity Verification Platform: The All-in-One Solution for Enterprise-Grade Identity Lifecycle Management

14.10.2025 14:00:00 CEST | Business Wire | Press Release

Share

Regula, a global developer of identity verification (IDV) solutions and forensic devices, has launched its brand-new Regula IDV Platform. This ready-to-use orchestration solution is designed to replace fragmented identity verification and management systems with a single, unified workflow. Built to scale according to an organization’s growth pace and fully vendor-agnostic, the platform enables businesses to manage every stage of the identity lifecycle, from onboarding through continuous reverification, without legacy constraints.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014313859/en/

Regula IDV Platform makes identity verification workflows organized and efficient

Today, nearly half of companies worldwide face the same identity verification challenges. Legacy systems lead to fragmentation and create blind spots in the processes. Enterprise environments often rely on a mix of services: one vendor for document checks, another for biometrics, a separate one for sanctions lists, etc., with data manually stitched together in inconsistent, sometimes chaotic ways. Every new application or service only adds another layer of complexity to the IDV infrastructure. This results in growing costs, increased security risks, and higher customer drop-off rates.

How the Regula IDV Platform addresses the biggest IDV pain points

  • One-stop-shop solution. Regula IDV Platform unites the most comprehensive set of identity checks, from documents to biometrics, eliminating repeated uploads and failed or unnecessary steps. As a result, it transforms onboarding into a single, seamless, and trusted flow with proprietary solutions for the entire identity journey. Users complete verification in seconds, not minutes, while organizations get a unified, enterprise-grade solution.
  • Flexible workflow orchestration. Regula IDV Platform makes complex, multi-step, multi-component identity verification workflows effortless. Unlike point solutions that handle single tasks, the platform supports complete end-to-end use cases. Easy customization capabilities allow companies to build adaptable verification processes aligned with their business needs.
  • Unified tools. The platform unites everything in one place: document and biometric checks, AML (Anti-Money Laundering) and PEP (Politically Exposed Persons) screening, databases, and more. Its vendor-agnostic architecture integrates with any tech stack and third-party systems, saving time and resources and closing blind spots.
  • Comprehensive identity management. Regula IDV Platform maintains a single source of truth with centralized user profiles, secure storage, and advanced analytics. It optimizes decision-making with transparent, reliable identity data and reduces complexity with single-flow user authentication.
  • Built-in compliance. From KYC (Know Your Customer) and AML to GDPR (General Data Protection) and CCPA (California Consumer Privacy Act) and more, all required checks are included by default. Regula IDV platform keeps complete audit trails, protects sensitive data and provides full control over it, and allows both on-premise and cloud deployment. Additionally, the platform supports age assurance to instantly confirm age, protect minors, and comply with local regulations.
  • ​​Lower costs, faster scaling. By consolidating multiple solutions into a single platform, Regula helps to reduce operational expenses. This agile platform grows together with businesses—easily adapting to changing processes, expanding integrations, regulatory updates, or increased workloads—without costly redevelopment or re-integration.

Beyond the orchestration of identity verification and management tools, the Regula IDV Platform ensures speed and flexibility. Its out-of-the-box, ready-to-use workflows and integrations let companies get started instantly without long setups. Powerful user data management and analytics tools help businesses store, process, and analyze identity data to optimize operations and decision-making. Thanks to its multilingual, multi-document, and multi-device support, the platform delivers native user experiences across geographies and channels and ensures reliable verification anywhere in the world.

Regula IDV Platform also supports the creation and reuse of digital credentials—verified identity attributes issued by trusted organizations such as banks, telecom providers, or government services. Once a user’s identity is confirmed during the KYC process, these credentials can be securely reused to authorize access to other services, with biometric verification ensuring authenticity at every step. This approach empowers businesses to streamline user journeys, enhance security, and take part in the growing digital identity ecosystem.

“For years, businesses have struggled with fragmented identity systems that are costly, slow, and hard to adapt. With Regula IDV Platform, we’ve taken our decades of in-house expertise in document and biometric verification and turned it into a single, unified solution. This platform gives enterprises the agility they need to scale, the flexibility to integrate with any system, and the orchestration capabilities to connect multiple processes into one seamless flow with the reliability of the most comprehensive identity checks—all while reducing complexity and cost. It’s the next step in helping organizations make identity verification both a strategic advantage and a seamless experience for their customers,” says Ihar Kliashchou, Chief Technology Officer at Regula.

To learn more about the capabilities of the new Regula IDV Platform, please visit Regula’s website.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been recognized in the 2025 Gartner® Magic Quadrant™ for Identity Verification.

Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014313859/en/

Contacts

Kristina – ks@regula.us

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye